Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 PROSTATE CANCER MEDICINE MARKET, BY DRUG TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. HORMONAL THERAPY DRUGS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. LHRH Antagonists
4.2.4.1. Market size and forecast
4.2.5. LHRH Analogs

4.2.5.1. Market size and forecast

4.2.6. Antiandrogens

4.2.6.1. Market size and forecast

4.2.7. Pipeline Drugs for Hormonal Therapy

4.2.7.1. Market size and forecast

4.3. CHEMOTHERAPY DRUGS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Off Patent Drugs

4.3.4.1. Market size and forecast

4.3.5. Patented Drugs

4.3.5.1. Market size and forecast

4.4. IMMUNOTHERAPY DRUGS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Off Patent Drugs

4.4.4.1. Market size and forecast

4.4.5. Patented Drugs

4.4.5.1. Market size and forecast

4.5. TARGET THERAPY DRUGS

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast Antiandrogens

4.5.3.1. Market size and forecast

4.5.4. Angiogenesis Inhibitor

4.5.4.1. Market size and forecast

4.5.5. Apoptosis Inducing

4.5.5.1. Market size and forecast

4.5.6. Signal Transduction Inhibitor

4.5.6.1. Market size and forecast

Chapter: 5 PROSTATE CANCER MEDICINE MARKET, BY GEOGRAPHY

5.1. OVERVIEW
5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast

5.2.3.1. U.S. market size and forecast
5.2.3.2. Canada market size and forecast
5.2.3.3. Mexico market size and forecast

5.2.4. North America Prostate Cancer Medicine Market by Drug Type

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast

5.3.3.1. Germany market size and forecast
5.3.3.2. France market size and forecast
5.3.3.3. UK market size and forecast
5.3.3.4. Italy market size and forecast
5.3.3.5. Spain market size and forecast
5.3.3.6. Rest of Europe market size and forecast

5.3.4. Europe Prostate Cancer Medicine Market by Drug Type

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast

5.4.3.1. Japan market size and forecast
5.4.3.2. China market size and forecast
5.4.3.3. India market size and forecast
5.4.3.4. Rest of Asia-Pacific market size and forecast

5.4.4. Asia-Pacific Prostate Cancer Medicine Market by Drug Type

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast

5.5.3.1. LatinAmerica market size and forecast
5.5.3.2. Middle East market size and forecast
5.5.3.3. Africa market size and forecast

5.5.4. LAMEA Prostate Cancer Medicine Market by Drug Type

Chapter: 6 COMPANY PROFILES

6.1. ASTRAZENECA PLC

6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments

6.2. ACTIVE BIOTECH

6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments

6.3. BRISTOL MYERS-SQUIBB

6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments

6.4. TEVA PHARMACEUTICALS INDUSTRIES LTD

6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments

6.5. JOHNSON & JOHNSON

6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments

6.6. PFIZER INC.

6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments

6.7. BAYER AG

6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments

6.8. ABBOTT LABORATORIES

6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments

6.9. ASTELLAS PHARMA INC

6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments

6.10. ROCHE HOLDING AG

6.10.1. Operating business segments
6.10.2. Business performance
6.10.3. Key strategic moves and developments